Related Experiment Video
Updated: Sep 3, 2025
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.0K
Site-Specific Considerations on Engineered T Cells for Malignant Gliomas.
Nirmeen Elmadany1,2, Obada T Alhalabi3,4, Michael Platten1,2,5,6,7
1DKTK (German Cancer Consortium), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Biomedicines
|July 27, 2022
Summary
Chimeric antigen receptor (CAR) T-cell therapy shows promise for malignant gliomas. This review explores locoregional delivery methods, aiming to improve CAR T-cell efficacy in treating brain tumors like glioblastoma.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular Therapy
Background:
- Immunotherapy has transformed cancer treatment, but efficacy in malignant gliomas (e.g., glioblastoma) remains limited.
- Chimeric antigen receptor (CAR) T-cell therapy has shown significant success in other solid tumors.
- Locoregional delivery of CAR T-cells may enhance efficacy in glioma compared to systemic administration.
Purpose of the Study:
- To review and summarize various CAR T-cell administration routes for malignant glioma.
- To discuss current and planned clinical trials of CAR T-cell therapy in glioma.
- To highlight the importance of administration route selection in combinatorial immunotherapeutic strategies for glioma.
Main Methods:
- Literature review of pre-clinical and clinical studies on CAR T-cell therapy in glioma.
- Summary of administration routes: locoregional, systemic (with/without focused ultrasound), intra-arterial, and nanoparticle-enhanced delivery.
- Discussion of published, ongoing, and planned clinical trials.
Main Results:
- Limited response to current immunotherapies in malignant gliomas.
- Promising clinical responses of CAR T-cell therapy in other solid tumors.
- Pre-clinical evidence suggests improved efficacy with locoregional CAR T-cell delivery in glioma.
Conclusions:
- Optimizing CAR T-cell administration routes is crucial for improving treatment outcomes in malignant glioma.
- Further research and clinical trials are needed to establish the most effective delivery strategies.
- Combinatorial immunotherapeutic approaches require careful consideration of administration routes for enhanced efficacy.
